Published in Mol Cell Biol on August 05, 2006
Negative regulation of CHK2 activity by protein phosphatase 2A is modulated by DNA damage. Cell Cycle (2010) 2.12
The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell (2009) 1.64
DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res (2009) 1.60
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther (2011) 1.57
A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev (2009) 1.42
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res (2011) 1.29
Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res (2012) 1.25
Pot1 and cell cycle progression cooperate in telomere length regulation. Nat Struct Mol Biol (2007) 1.23
Regulation of chk1. Cell Div (2009) 1.12
Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle (2010) 1.11
Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene (2010) 1.09
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Invest (2012) 1.09
14-3-3gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J (2010) 1.04
DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1. Oncotarget (2015) 1.04
ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response. Cell Death Differ (2010) 1.01
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin Cancer Res (2012) 1.01
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer (2013) 0.99
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget (2015) 0.98
Phosphatases in the cellular response to DNA damage. Cell Commun Signal (2010) 0.97
What goes on must come off: phosphatases gate-crash the DNA damage response. Trends Biochem Sci (2011) 0.97
Cell cycle G2/M arrest through an S phase-dependent mechanism by HIV-1 viral protein R. Retrovirology (2010) 0.97
The Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition. PLoS One (2012) 0.96
Replication checkpoint: tuning and coordination of replication forks in s phase. Genes (Basel) (2013) 0.95
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. Cell Cycle (2009) 0.95
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res (2013) 0.95
Retracted SMK-1/PPH-4.1-mediated silencing of the CHK-1 response to DNA damage in early C. elegans embryos. J Cell Biol (2007) 0.92
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. PLoS One (2012) 0.91
Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle. Cell Cycle (2014) 0.91
Turning off the G2 DNA damage checkpoint. DNA Repair (Amst) (2007) 0.91
Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit. Cell Cycle (2013) 0.88
The fork and the kinase: a DNA replication tale from a CHK1 perspective. Mutat Res Rev Mutat Res (2014) 0.87
Cheliensisin A inhibits EGF-induced cell transformation with stabilization of p53 protein via a hydrogen peroxide/Chk1-dependent axis. Cancer Prev Res (Phila) (2013) 0.86
PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol (2016) 0.85
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol Cancer Ther (2014) 0.83
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget (2015) 0.83
Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint. Cell Cycle (2013) 0.83
Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS One (2013) 0.82
Disruption of serine/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine/threonine protein kinase Chk1 (CHEK1). J Biol Chem (2011) 0.81
Epstein-Barr virus-encoded latent membrane protein 1 impairs G2 checkpoint in human nasopharyngeal epithelial cells through defective Chk1 activation. PLoS One (2012) 0.81
Response to DNA damage: why do we need to focus on protein phosphatases? Front Oncol (2013) 0.81
Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint. J Biol Chem (2014) 0.80
Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1. J Biol Chem (2013) 0.79
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget (2016) 0.79
DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging. Oxid Med Cell Longev (2012) 0.78
Glucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocks. Biochim Biophys Acta (2011) 0.77
Chk1 activity is required for BAK multimerization in association with PUMA during mitochondrial apoptosis. Cell Commun Signal (2014) 0.77
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res (2016) 0.76
AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. J Biol Chem (2015) 0.76
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest New Drugs (2015) 0.76
Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int J Cancer (2010) 0.76
Extensive RPA2 hyperphosphorylation promotes apoptosis in response to DNA replication stress in CHK1 inhibited cells. Nucleic Acids Res (2015) 0.75
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget (2016) 0.75
The G2 checkpoint-a node-based molecular switch. FEBS Open Bio (2017) 0.75
A Role for the Twins Protein Phosphatase (PP2A-B55) in the Maintenance of Drosophila Genome Integrity. Genetics (2016) 0.75
Checkpoint kinase 2 is required for efficient immunoglobulin diversification. Cell Cycle (2014) 0.75
Ataxin-3 promotes genome integrity by stabilizing Chk1. Nucleic Acids Res (2017) 0.75
Radiation activated CHK1/MEPE pathway may contribute to microgravity-induced bone density loss. Life Sci Space Res (Amst) (2015) 0.75
The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response. PLoS Pathog (2016) 0.75
NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget (2017) 0.75
The protein kinase complement of the human genome. Science (2002) 35.36
Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 22.23
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (2003) 20.13
ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer (2003) 16.06
Cell-cycle checkpoints and cancer. Nature (2004) 13.19
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev (2000) 11.49
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol (2005) 8.27
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol (2001) 7.26
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature (2001) 6.73
Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature (1993) 5.70
Identification and characterization of new elements involved in checkpoint and feedback controls in fission yeast. Mol Biol Cell (1994) 4.58
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol (2005) 4.54
Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res (1998) 4.52
Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev (2000) 4.38
A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature (2005) 4.33
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A (2002) 4.06
Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Genes Dev (2000) 3.96
Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell (2003) 3.58
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 3.49
gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell (2005) 3.24
Recombinant ATM protein complements the cellular A-T phenotype. Oncogene (1997) 2.95
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev (2005) 2.85
Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell (2005) 2.75
Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem (2003) 2.54
Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem (2002) 2.34
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res (2000) 2.20
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J (2004) 2.19
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem (2003) 2.18
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci (1992) 2.00
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ (2005) 1.98
Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene (2006) 1.93
Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol (2003) 1.71
The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res (2003) 1.70
DNA-PKcs function regulated specifically by protein phosphatase 5. Proc Natl Acad Sci U S A (2004) 1.60
Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition. EMBO J (2002) 1.58
PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation. EMBO J (2003) 1.50
Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. Genes Dev (2004) 1.47
Regulation of Chk1 kinase by autoinhibition and ATR-mediated phosphorylation. Mol Biol Cell (2004) 1.46
Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol (2000) 1.43
Fostriecin: chemistry and biology. Curr Med Chem (2002) 1.42
Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1. EMBO J (2004) 1.38
A maternal form of the phosphatase Cdc25A regulates early embryonic cell cycles in Xenopus laevis. Dev Biol (1999) 1.36
Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem (2003) 1.32
A role for PP1 in the Cdc2/Cyclin B-mediated positive feedback activation of Cdc25. Mol Biol Cell (2006) 1.31
Protein phosphatase 5 is required for ATR-mediated checkpoint activation. Mol Cell Biol (2005) 1.19
Protein phosphatase 2A antagonizes ATM and ATR in a Cdk2- and Cdc7-independent DNA damage checkpoint. Mol Cell Biol (2006) 1.15
The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. J Biol Chem (2001) 1.13
Regulation of Chk2 phosphorylation by interaction with protein phosphatase 2A via its B' regulatory subunit. Biol Cell (2004) 1.12
Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem (2003) 1.09
Nuclear localization of protein phosphatase 5 is dependent on the carboxy-terminal region. FEBS Lett (2001) 1.07
Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci (2005) 0.89
On the importance of protein phosphorylation in cell cycle control. Mol Cell Biochem (1993) 0.79
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A (2002) 4.06
Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A (2004) 3.59
Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med (2010) 2.44
Atypical PKC phosphorylates PAR-1 kinases to regulate localization and activity. Curr Biol (2004) 2.11
Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins. J Biol Chem (2004) 2.05
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A (2002) 1.81
Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe (2007) 1.71
Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol (2003) 1.71
LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab (2009) 1.70
DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res (2009) 1.60
Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol (2003) 1.58
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest (2012) 1.49
Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol (2005) 1.43
Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion. Proc Natl Acad Sci U S A (2009) 1.37
Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol Cancer Res (2003) 1.28
Contribution of p53 to metastasis. Cancer Discov (2014) 1.28
Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2002) 1.26
Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo. Proc Natl Acad Sci U S A (2007) 1.25
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat (2012) 1.12
New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. Mol Cell Biol (2006) 1.11
How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry (2003) 1.11
Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association. Proc Natl Acad Sci U S A (2008) 1.08
Family functioning in the caregivers of patients with dementia. Int J Geriatr Psychiatry (2004) 1.06
The Par-1/MARK family of protein kinases: from polarity to metabolism. Cell Cycle (2007) 1.03
Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal Chem (2006) 1.03
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav (2009) 1.01
The polarity protein Par1b/EMK/MARK2 regulates T cell receptor-induced microtubule-organizing center polarization. J Immunol (2009) 1.00
A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res (2008) 1.00
Treatment matching in the posthospital care of depressed patients. Am J Psychiatry (2005) 0.99
Okazaki fragment processing-independent role for human Dna2 enzyme during DNA replication. J Biol Chem (2012) 0.98
Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol Cell Biol (2008) 0.98
Does adjunctive family therapy enhance recovery from bipolar I mood episodes? J Affect Disord (2004) 0.98
Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev (2011) 0.98
Human cytomegalovirus protein pUL117 targets the mini-chromosome maintenance complex and suppresses cellular DNA synthesis. PLoS Pathog (2010) 0.97
Myt1 protein kinase is essential for Golgi and ER assembly during mitotic exit. J Cell Biol (2008) 0.97
CRL4(CDT2) targets CHK1 for PCNA-independent destruction. Mol Cell Biol (2012) 0.95
Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis. Mol Cell Biol (2010) 0.93
Burden, reward and family functioning of caregivers for relatives with mood disorders: 1-year follow-up. J Affect Disord (2004) 0.93
Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry (2006) 0.92
Impact of family functioning on quality of life in patients with psychogenic nonepileptic seizures versus epilepsy. Epilepsia (2011) 0.90
Longitudinal course of bipolar I disorder. Compr Psychiatry (2004) 0.90
Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice. J Biol Chem (2013) 0.89
Cognitive predictors of symptom return following depression treatment. J Abnorm Psychol (2003) 0.89
Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells. Mol Cell Biol (2011) 0.87
Family treatment for bipolar disorder: family impairment by treatment interactions. J Clin Psychiatry (2008) 0.86
Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom (2007) 0.86
Contributions made by CDC25 phosphatases to proliferation of intestinal epithelial stem and progenitor cells. PLoS One (2011) 0.86
Family functioning and mood disorders: a comparison between patients with major depressive disorder and bipolar I disorder. J Consult Clin Psychol (2006) 0.85
Quality of life and family functioning in caregivers of relatives with mood disorders. Psychiatr Rehabil J (2004) 0.84
Preventing recurrence of bipolar I mood episodes and hospitalizations: family psychotherapy plus pharmacotherapy versus pharmacotherapy alone. Bipolar Disord (2008) 0.83
Maintenance of insect cell cultures and generation of recombinant baculoviruses. Curr Protoc Mol Biol (2004) 0.83
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs (2015) 0.82
Family functioning in bipolar I disorder. J Fam Psychol (2006) 0.82
Methodological issues in conducting treatment trials for psychological nonepileptic seizures. J Neuropsychiatry Clin Neurosci (2007) 0.82
Phosphorylation of the E3 ubiquitin ligase RNF41 by the kinase Par-1b is required for epithelial cell polarity. J Cell Sci (2013) 0.81
Cdc25A regulation: to destroy or not to destroy--is that the only question? Cell Cycle (2003) 0.80
Family functioning in the caregivers of patients with dementia: one-year follow-up. Bull Menninger Clin (2006) 0.78
Characterizing the long-term course of individuals with major depressive disorder. J Nerv Ment Dis (2004) 0.78
Family focused therapy shortens recovery time from depression but not mania in adolescents with bipolar disorder. Evid Based Ment Health (2009) 0.78
Psychoeducation for caregivers of patients with chronic mood disorders. Bull Menninger Clin (2005) 0.78
STAR*D: have we learned the right lessons? Am J Psychiatry (2008) 0.75
Overview of the baculovirus expression system. Curr Protoc Mol Biol (2004) 0.75
Expression and purification of recombinant proteins using the baculovirus system. Curr Protoc Mol Biol (2004) 0.75
Family therapy and chronic depression. J Clin Psychol (2003) 0.75